Pulmatrix, Inc. PULM
1.32 USD +0.01 (+1.07%)
Nov 12, 2026, 10:32 AM EST
1.27 Day range 1.34
1.06 52-week range 4.98
- YTD
- -40.63%
- 1 year
- -72.87%
News
globenewswire.com Eos SENOLYTIX's PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference Data to highlight PTC-2105's attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos's lead clinical candidate in development for elderly…
benzinga.com Eos SENOLYTIX Presents New Preclinical Survival, Healthspan, Mechanism-Of-Action Data For Its PTC-2105 Candidate At 17th World Congress On Targeting Mitochondria 2026 Eos SENOLYTIX, Inc. ("Eos" or the "Company") a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today presented new preclinical survival, healthspan and
benzinga.com Eos SENOLYTIX Advances Lead Candidate MitoXcel Geropeptide PTC-2105 Toward First-In-Human Studies For Sarcopenia And Sarcopenic Obesity Advancing PTC-2105 Toward the ClinicEos is in the preclinical stage of development of PTC-2105 and is conducting IND-enabling studies to support the initiation of first-in-human clinical trials,…
benzinga.com Eos SENOLYTIX CEO To Deliver Industry Keynote On Advancing Mitochondrial-Targeted Geropeptide Medicine; Co. Expects To Close Pulmatrix Merger In Q4 Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and- benzinga.com Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.29) per share. This is a 30.95 percent increase over losses of $(0.42) per share from the same period last year.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Pulmatrix Q1 EPS $(0.32) Up From $(0.50) YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.32) per share. This is a 36 percent increase over losses of $(0.50) per share from the same period last year.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Pulmatrix Signs Agreement To Acquire Eos SENOLYTIX; Financial Terms Undisclosed Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com Pulmatrix Q4 EPS $(0.25) Up From $(0.55) YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.25) per share. This is a 54.55 percent increase over losses of $(0.55) per share from the same period last year.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Pulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule…- benzinga.com Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.24) per share. This is a 66.2 percent increase over losses of $(0.71) per share from the same period last year.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.42) per share. This is a 73.58 percent increase over losses of $(1.59) per share from the same period last year.
- benzinga.com Pulmatrix Seeks Divestment Of Clinical Assets And iSPERSE Inhalation Technology Amid Advancements In Migraine, COPD, And Antifungal Treatments Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ TechnologyiSPERSE™ TechnologyiSPERSE™ particles are engineered with a small, dense and dispersible profile to exceed
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Pulmatrix Q1 EPS $(0.50) Down From $0.23 YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.50) per share. This is a 317.39 percent decrease over earnings of $0.23 per share from the same period last year.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Pulmatrix And Cullgen Announce Proposed Merger; Pre-Merger Pulmatrix Stockholers To Own ~3.6% Of Combined Company; Pre-Merger Cullgen Stockholders To Own ~96.4% Of Combined Company Under Name Cullgen Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of…
- benzinga.com Pulmatrix Q3 EPS $(0.71) Up From $(1.03) YoY, Sales $366.00K Down From $1.75M YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.71) per share. This is a 31.07 percent increase over losses of $(1.03) per share from the same period last year. The company reported $366.00…
- benzinga.com Pulmatrix Announces Peer-Reviewed Publication Headache: The Journal Of Head And Face Pain, Clinical Results For Its Orally Inhaled DHE For Acute Migraine Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE.Self-administered PUR3100 showed…
- benzinga.com Pulmatrix Q4 EPS $(0.57) Beats $(1.04) Estimate, Sales $2.20M Beat $1.77M Estimate Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.04) by 45.19 percent. This is a 50 percent increase over losses of $(1.14) per…
- benzinga.com Pulmatrix Stops PUR1900 Phase 2B Study Patient Enrollment And Closing Study, In Agreement With Partner Cipla, To Preserve Cash And Facilitate Strategic Alternatives Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix…
- benzinga.com Pulmatrix Q3 EPS $(1.03) Beats $(1.05) Estimate, Sales $1.75M Miss $1.86M Estimate Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.05) by 1.9 percent. This is a 28.97 percent increase over losses of $(1.45) per…
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.
- benzinga.com Pulmatrix Announces FDA Acceptance Of IND Application For PUR3100 To Treat Acute Migraine Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 225 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 59 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 99 stocks hit new 52-week lows.
- benzinga.com Pulmatrix Announces Publication On Physiologically Based Pharmacokinetic Modelling Of Potential Drug-Drug Interactions With PUR1900, Orally Inhaled Itraconazole Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazolePulmatrix is currently…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Pulmatrix, Maintains $10 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.
benzinga.com Pulmatrix Q2 EPS $(1.04) Up From $(1.36) YoY, Sales $1.84M Up From $1.33M YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.04) per share. This is a 23.53 percent increase over losses of $(1.36) per share from the same period last year. The company reported $1.84…- benzinga.com Pulmatrix Announces Submission Of IND Application To FDA To Initiate A Phase 2 Trial Of Investigational Drug PUR3100 To Treat Acute Migraine Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 120 stocks hit new 52-week lows.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Pulmatrix, Maintains $10 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.
- benzinga.com Pulmatrix Q1 EPS $(1.22) Up From $(1.51) YoY, Sales $1.50M Up From $1.16M YoY Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.22) per share. This is a 19.21 percent increase over losses of $(1.51) per share from the same period last year. The company reported $1.50…
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 185 companies achieved new lows for the year.
- benzinga.com Pulmatrix Announces Year-End And Q4 Financial 2022 Results And Provides Corporate Update; $35.6M In Cash And Cash Equivalents At The End Of 2022 Providing Cash Runway Into Q2 2024 PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 89 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 479 stocks made new 52-week lows.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Pulmatrix, Maintains $10 Price Target HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.
- benzinga.com Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket Gainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading.
- benzinga.com 93 Biggest Movers From Friday Gainers Inspirato Incorporated (NASDAQ: ISPO) shares surged 50.5% to close at $54.90.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning, 282 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.